Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party

Blood (2011) 118 (21): 453.

https://doi.org/10.1182/blood.V118.21.453.453

Published: 2011

Journal Articles

Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients,

Simona Soverini, Caterina De Benedittis, Alessandra Gnani, Ilaria Iacobucci, PhD, Domenico Russo, Federica Cattina, MD, Fausto Castagnetti, Gabriele Gugliotta, Cristina Papayannidis, Antonella Vitale, Loredana Elia, Robin Foà, Francesca Palandri, Annalisa Lonetti, Maria Teresa Bochicchio, Sandra Durante, Gianantonio Rosti, MD, Michele Baccarani, MD, Giovanni Martinelli

Blood (2011) 118 (21): 3775.

https://doi.org/10.1182/blood.V118.21.3775.3775

Published: 2011

Journal Articles

Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial)

Blood (2011) 118 (21): 2756.

https://doi.org/10.1182/blood.V118.21.2756.2756

Published: 2011

Journal Articles

A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)

Blood (2011) 118 (21): 805.

https://doi.org/10.1182/blood.V118.21.805.805

Published: 2011

Journal Articles

High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 ,

Carolina Terragna, PhD, Marina Martello, Sandra Durante, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Giulia Perrone, MD, Beatrice Anna Zannetti, MD, Enrica Borsi, PhD, Michele Baccarani, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2011) 118 (21): 3935.

https://doi.org/10.1182/blood.V118.21.3935.3935

Published: 2011

Journal Articles

PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients

Blood (2011) 118 (21): 1429.

https://doi.org/10.1182/blood.V118.21.1429.1429

Published: 2011

Journal Articles

Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies

Blood (2011) 118 (21): 112.

https://doi.org/10.1182/blood.V118.21.112.112

Published: 2011

Journal Articles

HIF 1 Alpha: A Suitable Target for Multiple Myeloma

Giulia Perrone, MD, Enrica Borsi, PhD, Carolina Terragna, PhD, Sandra Durante, Marina Martello, Michela Aluigi, PhD, Manuela Mancini, PhD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Beatrice Anna Zannetti, MD, Giovanni Martinelli, MD, Maria Alessandra Santucci, MD, Michele Baccarani, MD, Michele Cavo, MD

Blood (2011) 118 (21): 2901.

https://doi.org/10.1182/blood.V118.21.2901.2901

Published: 2011

Journal Articles

Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509

Domenico Russo, Giuliana Alimena, Chiara Colombi, Massimo Breccia, Simona Soverini, Ilaria Iacobucci, PhD, Federica Cattina, MD, Giovanni Martinelli, MD, Nicoletta Testoni, Anna Marina Liberati, Viviana Appolloni, Mario Tiribelli, Renato Fanin, Felicetto Ferrara, MD, Mario Annunziata, MD, Elena Trabacchi, Daniele Vallisa, MD, Antonio De Vivo, Fausto Castagnetti, Miriam Fogli, Sandra Durante, Francesco Di Raimondo, MD, Fabio Stagno, A. M. Carella, G. Pica, Alessandra Iurlo, M.D., Tommaso Radice, Patrizia Pregno, MD, Umberto Vitolo, MD, Elisabetta Abruzzese, Paolo de Fabritiis, Maurizio Longinotti, MD, Simonetta Pardini, Caterina Musolino, MD, Sabina Russo, Marco Gobbi, MD, Ivana Pierri, Gianluca Gaidano, Monia Lunghi, M.D., Giuseppe Visani, Sara Barulli, Mario Cazzola, Serena Merante, Cristina Skert, MD, Michele Malagola, Gianantonio Rosti, MD, Michele Baccarani, MD

Blood (2011) 118 (21): 786.

https://doi.org/10.1182/blood.V118.21.786.786

Published: 2011

Journal Articles

Gas1 and Kif27 Genes Are Strongly up-Regulated Biomarkers of Hedgehog Inhibition (PF-04449913) on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients

Blood (2011) 118 (21): 1535.

https://doi.org/10.1182/blood.V118.21.1535.1535

Published: 2011

Journal Articles

The Elevated Expression of FBP1 , a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients.

Carolina Terragna, Sandra Durante, Annalisa Astolfi, Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Marilina Amabile, Ilaria Iacobucci, Simona Soverini, Giuliana Alimena, MD, Massimo Breccia, MD, Fabrizio Pane, MD, Giuseppe Saglio, MD, PhD, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2010) 116 (21): 3399.

https://doi.org/10.1182/blood.V116.21.3399.3399

Published: 2010

Journal Articles

Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients

Blood (2010) 116 (21): 3562.

https://doi.org/10.1182/blood.V116.21.3562.3562

Published: 2010

Journal Articles

Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis

Blood (2010) 116 (21): 861.

https://doi.org/10.1182/blood.V116.21.861.861

Published: 2010

Journal Articles

Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities

Blood (2010) 116 (21): 781.

https://doi.org/10.1182/blood.V116.21.781.781

Published: 2010

Journal Articles

CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.

Carolina Terragna, Sandra Durante, Annalisa Astolfi, Francesca Palandri, Fausto Castagnetti, Gianantonio Rosti, Nicoletta Testoni, Simona Luatti, Ilaria Iacobucci, PhD, Thea Kalebic, MD, Simona Soverini, Marilina Amabile, Angela Poerio, Michele Baccarani, Giovanni Martinelli

Blood (2009) 114 (22): 2174.

https://doi.org/10.1182/blood.V114.22.2174.2174

Published: 2009

Journal Articles

IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients.

Blood (2009) 114 (22): 912.

https://doi.org/10.1182/blood.V114.22.912.912

Published: 2009

Journal Articles

C-Myc Mediated Regulation of Multidrug Resistance Genes in Chronic Myeloid Leukaemia Cd34+ Cell Progenitors.

Samuele Gherardi, Simona Soverini, Ph.D., Nunzio Iraci, Ph.D., Carolina Terragna, Ph.D., Emanuele Valli, Sandra Durante, Annalisa Astolfi, Ph.D., Roberto Bernardoni, Ph.D., Thea Kalebic, MD, Fabrizio Pane, MD, Giuseppe Saglio, MD, Giovanni Martinelli, MD, Michele Baccarani, MD, Giovanni Perini, Ph.D.

Blood (2009) 114 (22): 3252.

https://doi.org/10.1182/blood.V114.22.3252.3252

Published: 2009

Journal Articles

High-Resolution Genome Wide Copy Number Alteration (CNA) and Loss of Heterozigosity (LOH) Analysis in Chronic Myeloid Leukemia (CML) Shows That High and Intermediate Sokal Risk Pts (Pts) Have Multiple Losses Targeting Genes Involved in DNA Repair.

Simona Soverini, PhD, Sabrina Colarossi, Alessandra Gnani, Annalisa Astolfi, Serena Formica, Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Angela Poerio, Ilaria Iacobucci, Marilina Amabile, Giulia Marzocchi, Simona Luatti, Carolina Terragna, Sandra Durante, Nicoletta Testoni, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2009) 114 (22): 3262.

https://doi.org/10.1182/blood.V114.22.3262.3262

Published: 2009

Journal Articles

Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile.

Blood (2009) 114 (22): 2811.

https://doi.org/10.1182/blood.V114.22.2811.2811

Published: 2009

Journal Articles

Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.

Blood (2009) 114 (22): 3283.

https://doi.org/10.1182/blood.V114.22.3283.3283

Published: 2009

NARROW

Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party

Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients,

Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial)

A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM)

High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 ,

PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients

Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies

HIF 1 Alpha: A Suitable Target for Multiple Myeloma

Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509

Gas1 and Kif27 Genes Are Strongly up-Regulated Biomarkers of Hedgehog Inhibition (PF-04449913) on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients

The Elevated Expression of FBP1 , a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients.

Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients

Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative and Quantitative Analysis

Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities

CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.

IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients.

C-Myc Mediated Regulation of Multidrug Resistance Genes in Chronic Myeloid Leukaemia Cd34+ Cell Progenitors.

High-Resolution Genome Wide Copy Number Alteration (CNA) and Loss of Heterozigosity (LOH) Analysis in Chronic Myeloid Leukemia (CML) Shows That High and Intermediate Sokal Risk Pts (Pts) Have Multiple Losses Targeting Genes Involved in DNA Repair.

Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile.

Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only